Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil (BRIGHT)
A Single-arm Observational Study to Characterize the Epidemiological Profile of Patients With IDH-mutant Diffuse Gliomas Diagnosed From 2021 in Brazil - BRIGHT Study (LACOG 0425)
This is a real-world, retrospective, non-interventional, single-arm, multi-center Brazilian study that will include patients diagnosed with IDH-mutant diffuse glioma in Brazil from 2021. Eligible patients will be included in this study to have their medical charts data collected by site personnel. Included patients won´t be requested to attend protocol-specific visits and treatment decisions and disease management will be at the investigator's discretion
調査の概要
状態
詳細な説明
This study is designed to describe the epidemiological, anti-cancer treatment and clinical outcomes of patients with IDH-mutant diffuse glioma in Brazil. Patients ≥ 12 years old diagnosed with IDH-mutant diffuse gliomas from 2021 will be included. In the baseline medical chart evaluation, data on epidemiology, pathological, treatment patterns, toxicities, and clinical outcomes will be collected. LACOG (Sponsor) will be responsible for managing data from this study, including quality verification. Manually entered data will be captured via EDC using eCRFs. The EDC system used in this study will be REDCap (Research Electronic Data Capture) - that meets the established standards approved for the safety of health information and is validated. REDCap is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for continuous data downloads for common statistical packages; and 4) procedures for data integration and interoperability with external sources. The system also meets ICH guidelines on electronic handling of study data and will be available for audit upon request. Patient confidentiality will be strictly maintained.
An informed consent form will be offered to all living patients. The consent will be unnecessary in patients that could not be reached or that have passed away (died) as per regulation Res. CNS 466/12 item IV.8. Consent will be obtained from legal guardians for patients between the ages of 12 and 17 years old as per Brazilian regulation.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Laura Voelcker
- 電話番号:+55 (51) 3384.5334
- メール:laura.voelcker@lacog.group
研究連絡先のバックアップ
- 名前:Project Manager
- 電話番号:+55 (51) 3384.5334
- メール:lacog0425@lacog.group
研究場所
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、40050-050
- まだ募集していません
- IESG Instituto de Ensino da Saúde e Gestão
-
主任研究者:
- Teresa Fonseca
-
Salvador、Estado de Bahia、ブラジル、40050-410
- まだ募集していません
- Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel (Oncoclínicas)
-
主任研究者:
- Daniela Oliveira
-
Salvador、Estado de Bahia、ブラジル、41950-640
- まだ募集していません
- ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia
-
主任研究者:
- Aknar Calabrich
-
-
Federal District
-
Brasília、Federal District、ブラジル、70390-140
- まだ募集していません
- OncoStar Rede D'or DF
-
主任研究者:
- Daniel Marques
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30360-680
- まだ募集していません
- Oncocentro de Minas Gerais (Oncoclínicas)
-
主任研究者:
- Flávio Brandão
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90470-340
- 募集
- Futtura Oncologia - Hub de Pesquisa Clínica
-
主任研究者:
- Luisa Fasolo
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、ブラジル、20230-130
- まだ募集していません
- INCA - Instituto Nacional de Câncer
-
コンタクト:
- 電話番号:+5521991169827
-
主任研究者:
- Carolina Pessôa
-
Rio de Janeiro、Rio de Janeiro、ブラジル、22793-080
- まだ募集していません
- Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)
-
主任研究者:
- Victor Teixeira
-
-
São Paulo
-
São Paulo、São Paulo、ブラジル、01308-050
- まだ募集していません
- Hospital Sírio-Libanês SP
-
主任研究者:
- Marcos Maldaun
-
São Paulo、São Paulo、ブラジル、01323-030
- まだ募集していません
- BP - A Beneficência Portuguesa de São Paulo
-
主任研究者:
- Camilla Yamada
-
São Paulo、São Paulo、ブラジル、04039-001
- まだ募集していません
- GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer
-
主任研究者:
- Andrea Cappellano
-
São Paulo、São Paulo、ブラジル、05653-000
- まだ募集していません
- HIAE - Hospital Israelita Albert Einstein
-
主任研究者:
- Suzana Malheiros
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Male or female patients (aged 12 years or older), able to provide informed consent, diagnosed with IDH-mutant diffuse glioma in Brazil from 2021.
説明
Inclusion Criteria:
- Male or female patients (aged 12 years or older);
- Histologically confirmed diagnosis of diffuse glioma from 2021;
- Confirmed IDH mutation identified by IHC or PCR/NGS;
- Willing and able to provide written informed consent, applicable to living patients. In case of patients <18 years of age, their legal guardians should provide an written informed consent
Exclusion Criteria:
Since the study is observational, there are no extensive Exclusion Criteria, but the following criteria excludes patients from the study to ensure data collected by be analyzed from a broader context and compared to other studies of this kind:
- Patients without medical record available (lost, empty or irretrievable clinical information).
- Living patients and/or legal guardians of patients <18 years of age who did not accept or withdrew their consent from the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:RETROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
IDH-mutant diffuse glioma cohort
Male or female patients aged 12 years or older histologically confirmed diagnosis of diffuse glioma from 2021 and confirmed IDH mutation identified by IHC or PCR/NGS. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Epidemiological profile of patients with IDH-mutant diffuse gliomas
時間枠:Baseline
|
Characterization of demographic and socioeconomic characteristics, including age, weight, height, race, educational level, income, marital status, living status, and risk factors |
Baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:From date of diagnosis up to at least 30 months.
|
Date of initial diagnosis/treatment to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed via CNS imaging per investigator assessment. |
From date of diagnosis up to at least 30 months.
|
|
Overall Survival (OS)
時間枠:From date of diagnosis up to at least 30 months.
|
Percentage of participants alive and time from diagnosis to death from any cause. |
From date of diagnosis up to at least 30 months.
|
|
Objective Response Rate (ORR)
時間枠:Up to 30 months.
|
Evaluation of objective tumor response to therapies assessed via central nervous system (CNS) imaging by investigator assessment. |
Up to 30 months.
|
|
Treatment Patterns and Sequencing
時間枠:Up to 30 months.
|
Characterization of systemic therapies, radiation therapy details (dose, fractions), surgical procedures, and treatment sequencing. |
Up to 30 months.
|
|
Dose Reduction and Discontinuation Rates
時間枠:up to 30 months
|
Percentage of participants requiring dose reduction or treatment discontinuation and reasons for modification/discontinuation. |
up to 30 months
|
|
Time to Next Intervention (TTNI)
時間枠:Up to 30 months.
|
Time from the date of first systemic therapy initiation to the date of initiation of subsequent anticancer therapy. |
Up to 30 months.
|
|
Interval Between Last Surgery and First Systemic Therapy or Radiotherapy
時間枠:Baseline/up to 30 months
|
Median interval in days/months between the date of the last glioma surgery and the initiation of the first systemic therapy or radiotherapy. |
Baseline/up to 30 months
|
|
Time From Initial Diagnosis to First Systemic or Radiotherapy Initiation
時間枠:Baseline/up to 30 months
|
Time in days/months from the date of initial pathological diagnosis to the start of first systemic therapy or radiotherapy. |
Baseline/up to 30 months
|
|
Prevalence of Seizures at First Systemic Therapy
時間枠:up to 30 months
|
Percentage of patients experiencing seizures for any reason at or during the initiation of the first systemic therapy. |
up to 30 months
|
|
Karnofsky Performance Status (KPS) Score
時間枠:Baseline/up to 30 months
|
Functional status evaluated using the Karnofsky Performance Status scale (range 0-100%). |
Baseline/up to 30 months
|
|
Karnofsky Performance Status (KPS) Deterioration
時間枠:up to 30 months
|
Assessment of KPS score decline/deterioration over time during the first systemic therapy. |
up to 30 months
|
|
Frequency and Results of Molecular Testing
時間枠:Baseline
|
Description of the proportion and specific results of molecular testing (e.g., IDH mutation testing by IHC or PCR/NGS, 1p/19q codeletion, CDKN2A/B) performed in routine clinical practice in Brazil. |
Baseline
|
協力者と研究者
捜査官
- 主任研究者:Carolina Pêssoa、Instituto Nacional do Câncer
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- LACOG 0425
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。